KoBioLabs, Inc.
Financials
Valuation Metrics
KoBioLabs, Inc.'s Market Cap is ₩516B. At end of 2025 it was ₩1113B. Ranked #1760 of 2,421 in KR market (top 73%), #1071 of 1,640 on KOSDAQ (top 65%), #187 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 81%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 51.56B KRW | KR#1,760/2,421 Sec#187/231 |
| Revenue | 75.41B KRW | KR#1,577/2,421 Sec#101/231 |
| Net Income | -4.79B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 92.03B KRW | KR#1,844/2,421 Sec#147/231 |
| Net Assets | 45.42B KRW | KR#1,969/2,421 Sec#168/231 |
| Employees | 57 | KR#1,989/2,421 Sec#177/231 |
| Value | ||
| P/B | 1.14x | KR#1,573/2,421 Sec#105/231 |
| P/S | 0.68x | KR#1,127/2,421 Sec#55/231 |
| FCF Yield | -11.79% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -10.54% | KR#1,954/2,421 Sec#147/231 |
| ROA | -5.20% | KR#1,940/2,421 Sec#139/231 |
| Op. Margin | -10.70% | KR#2,002/2,421 Sec#135/231 |
| Revenue Growth | 8.58% | KR#976/2,421 Sec#96/231 |
| Financial Health | ||
| Debt Ratio | 102.63% | KR#1,581/2,421 Sec#182/231 |
| Total Debt | 16.47B KRW | KR#1,455/2,421 Sec#120/231 |
| FCF | -6.08B KRW | KR#1,552/2,421 Sec#123/231 |
| Cash | 14.63B KRW | KR#1,449/2,421 Sec#117/231 |
| Current Ratio | 3.38x | KR#486/2,421 Sec#71/231 |
| Performance | ||
| 1Y Return | -56.26% | KR#2,153/2,421 Sec#201/231 |
| 1M Return | -10.91% | KR#2,132/2,421 Sec#178/231 |
| From 52W High | -69.59% | KR#2,184/2,421 Sec#189/231 |
| 1Y MDD | -60.49% | KR#1,506/2,421 Sec#123/231 |
| Trading | ||
| Volume | 38,044 shares | KR#1,261/2,421 Sec#125/231 |
| Trading Value | 101.0M KRW | KR#1,552/2,421 Sec#154/231 |
| Foreign Own. | 2.80% | KR#1,354/2,421 Sec#126/231 |
| Per Share | ||
| EPS | -246 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,339 KRW | KR#1,995/2,421 Sec#162/231 |
Company Info
KoBioLabs, established in 2014 and listed on KOSDAQ in 2020, is a microbiome-specialized biotech company. It develops human microbiome-based therapeutics like CUREbiotics and operates a health functional food business, producing and selling probiotic products via its subsidiary, WeBiome. Through its Smartiome 2.0 new drug development platform, the company has established a therapeutic pipeline for immune diseases and secured core competitiveness in the bio sector by commencing global clinical trials for microbiome new drugs.